{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for l root_names_stdName in Standardized Name (approximate match)
Status:
Investigational
Source:
NCT03944096: Phase 2 Interventional Unknown status Rheumatoid Arthritis
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02824419: Phase 2/Phase 3 Interventional Unknown status Pulmonary Sarcoidosis
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03435848: Phase 2 Interventional Completed Acute Myeloid Leukemia
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03275974: Phase 1 Interventional Active, not recruiting RAS Wild Type
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:odatroltide [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02592824: Phase 3 Interventional Completed Coronary Artery Bypass Surgery
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02173457: Phase 3 Interventional Completed Type 2 Diabetes
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02483182: Phase 2 Interventional Completed Herpes Labialis
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
SIS Shulov Innovative Science is developing ZEP 3, a short synthetic peptide. This drug was studied in phase II clinical trial for the treatment of cold sores (Herpes labialis). In addition, was shown that ZEP-3 exhibited analgesic activity in various indications such as osteoarthritis, herpes labialis and ocular pain. In parallel, the company is planning a phase II clinical study in atopic dermatitis.
Status:
Investigational
Source:
NCT03593421: Phase 2 Interventional Withdrawn Panel Reactive Antibodies
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02772861: Not Applicable Interventional Completed Intestinal Diseases
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
